Molecular evolution of chronic myeloid leukaemia

Seminars in Cancer Biology

Volumn 11, Issue 4, 2001, Pages 313-322

  Shteper, Pesach J ^a   Ben Yehuda, Dina ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

ABL; Chronic myeloid leukaemia; Dormancy; Methylation; Progression

Indexed keywords

DNA;

ARTICLE; BONE MARROW TRANSPLANTATION; CHROMOSOME 17; CHROMOSOME 19; CHROMOSOME 22; CHROMOSOME 8; CHROMOSOME ABERRATION; CHRONIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA METHYLATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; ONCOGENE;

EID: 0034865264     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.2001.0387     Document Type: Article

References (85)

1. Chromosomal breakpoints within the first intron of the ABL gene are nonrandom in patients with chronic myelogenous leukemia
2. Heritable fragile sites in cancer
3. Chronologic sequence in appearance of clinical and laboratory findings characteristic of chronic myelocytic leukemia
4. Evidence for a multistep pathogenesis of chronic myelogenous leukemia
5. BCR/ABL rearrangement and leukemia phenotype
6. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
7. A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia
8. Neutrophilic-chronic myeloid leukemia: A distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction)
9. Abl tyrosine kinase in signal transduction and cell-cycle regulation
10. Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations
11. Increased neutrophil respiratory burst in bcr-null mutants
12. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity
13. Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases
14. A coiled-coil tetramerization domain of BCR-ABL is essential for the interactions of SH2-containing signal transduction molecules
15. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia
16. The molecular biology of chronic myeloid leukemia
17. Differences between normal and CML stem cells: Potential targets for clinical exploitation
18. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway
19. Growth factor-mediated terminal differentiation of chronic myeloid leukemia
20. Integrin-mediated regulation of hematopoiesis: Do BCR/ABL-induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors?
21. Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras
22. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia
23. The proto-oncogene product p120CBL and the adaptorproteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3′ kinase pathway
24. Interferon-alpha effects on stromal compartment of normal and chronic myeloid leukemia hematopoiesis
25. Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway
26. Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate
27. Reversibility of acute B-cell leukaemia induced by BCR-ABL1
28. Very low level of major BCR-ABL expression in blood of some healthy individuals
29. HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML)
30. The cytogenetic scenario of chronic myeloid leukemia
31. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia
32. p53 loss and point mutations are associated with suppression of apoptosis and progression of CML into myeloid blastic crisis
33. Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies
34. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia
35. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies
36. Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: Biological implications
37. Distinct expression patterns of the p53-homologue p73 in malignant and normal hematopoiesis assessed by a novel real-time reverse transcription-polymerase chain reaction assay and protein analysis
38. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression
39. Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia
40. Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase
41. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry
42. CpG-rich islands and the function of DNA methylation
43. Number of CpG islands and genes in human and mouse
44. Evolution of X-chromosome inactivation in mammals
45. DNA methylation represses transcription in vivo
46. DNA methylation models histone acetylation
47. Retrovirus-induced de novo methylation of flanking host sequences correlates with gene inactivity
48. The role of DNA methylation in cancer genetic and epigenetics
49. Alterations in DNA methylation: A fundamental aspect of neoplasia
50. DNA hypermethylation in tumorigenesis: Epigenetics joins genetics
51. DNA methylation changes in hematologic malignancies: Biologic and clinical implications
52. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia
53. Promoter demethylation accompanies reactivation of tine HOX11 proto-oncogene in leukemia
54. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype
55. Acceleration of chronic myeloid leukemia correlates with calcitonin gene hypermethylation
56. Increasing methylation of the calcitonin gene during disease progression in sequential samples from CML patients
57. Calcitonin gene methylation in chronic myeloproliferative disorders
58. Hypermethylation of the WT1 and calcitonin gene promoter regions at chromosome 11p in human colorectal cancer
59. The short arm of chromosome 11 is a "hot spot" for hypermethylation in human neoplasia
60. Methylation of the major breakpoint cluster region (M-bcr) in Philadelphia-positive CML
61. Methylation status of the major breakpoint cluster region in Philadelphia chromosome negative leukemias
62. Loss of imprinting of human insulin-like growth factor II gene, IGF2, in acute myeloid leukemia
63. Genomic imprinting and carcinogenesis
64. Loss of imprinting in disease progression in chronic myelogenous leukemia
65. ABL1 methylation in Ph-positive ALL is exclusively associated with the P210 form of BCR-ABL
66. Prognostic significance of c-ABL methylation in chronic myelogenous leukemia: Still an open question
67. ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia
68. Molecular follow-up of disease progression and interferon therapy in chronic myelocytic leukemia
69. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia
70. Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene
71. Methylation of the ABL1 promoter in chronic myelogenous leukemia: Lack of prognostic significance
72. Antagonistic effects of ABL and BCRABL proteins on proliferation and the response to genotoxic stress in normal and leukemic myeloid cells
73. Chronic myelogenous leukemia in nonlymphoid blastic phase: Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients
74. Detection and quantification of residual disease in chronic myelogenous leukemia
75. Cytogenetic response to autografting in chronic myelogenous leukemia correlates with the amount of BCR-ABL positive cells in the graft
76. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3
77. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?
78. Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukaemia
79. Relapse of chronic myeloid leukaemia 14 years after allogeneic bone marrow transplantation
80. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
81. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia
82. T-cell depletion of HLA-identical transplants in leukemia
83. Identical-twin bone marrow transplants for leukemia
84. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
85. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation